Look for:

Our offer for

KUROS BIOSCIENCES AG


ISIN:
CH0325814116
WKN:
32581411
2019/06/28 09:05:00
Price
1.4054 EUR
Difference 5.43% (0.07)

General attributes

ISINCH0325814116
SymbolKURN
ExchangeFrankfurt
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)479 EUR
BenchmarkSWISS MARKET INDEX

Market data

Bid (Bid size)-
Ask (Ask size)-
Open1.4054 EUR
High1.65 EUR
Low1.65 EUR
Close (prev. day)1.3330 EUR
VWAP1.588559 EUR
Volume (pcs)0
Trading volume0.00
Number of trades1
Last size0

Futures and Options

Related Futures-
Related Options-

PDF Downloads

Company report: KUROS BIOSCIENCES AGPDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2019/06/28 09:05:00
Price
1.4054 EUR
Difference 5.43% (0.07)

General attributes

ISINCH0325814116
SymbolKURN
ExchangeFrankfurt
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)479 EUR
BenchmarkSWISS MARKET INDEX

Market data

Bid (Bid size)-
Ask (Ask size)-
Open1.4054 EUR
High1.65 EUR
Low1.65 EUR
Close (prev. day)1.3330 EUR
VWAP1.588559 EUR
Volume (pcs)0
Trading volume0.00
Number of trades1
Last size0

Performance and Risk

6m1Y3Y
Perf (%)---
Perf (abs.)---
Beta0.730.770.56
Volatility---
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)- EUR (-)
Ø price 30 days | Ø volume 30 days (pcs.)- EUR (-)
Ø price 100 days | Ø volume 100 days (pcs.)- EUR (-)
Ø price 250 days | Ø volume 250 days (pcs.)- EUR (-)
YTD High | date- EUR (-)
YTD Low | date- EUR (-)
52 Weeks High | date- EUR (-)
52 Weeks Low | date- EUR (-)

All listings for KUROS BIOSCIENCES AG

Exchange  DateTimePriceTrading volume (mio.)Number of trades
FINRA other OTC Issues2024/07/1615:3113.70 USD0.012
Frankfurt2019/06/2809:051.4054 EUR0.001
London Stock Exchange2022/12/1617:521.505 CHF0.051
SIX Swiss Exchange2024/07/1717:3012.58 CHF1.72530

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=2489&ID_TYPE_IMAGE_LOGO=2

Contact Details

KUROS BIOSCIENCES LTD.
- -
Wagistrasse 25 - 8952 Schlieren
Telefon: +41-44-733-47-47
Fax: +41-44-733-47-40
E-mail: info@kuros.ch

PDF Downloads

Company report: KUROS BIOSCIENCES AGPDF Download

Company Profile

Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland.

Members of Management Board

Chris FairChairman of Managing Board
Philippe SaudanMember of Executive Committee
Joost de BruijnMember of Executive Committee
Daniel GeigerMember of Executive Committee
John GriffinMember of Executive Committee
Sjoerd MustersMember of Executive Committee

Board of directors

Joost de BruijnMember of the administrative board
Albert ArpMember of the administrative board
Oliver WalkerMember of the administrative board
Clemens van BlitterswijkChairman of the administrative boar





Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. Please read more information here

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer